20. The use according to claim 1, wherein the medicament is manufactured for administering neratinib and capecitabine simultaneously.

21. The use according to claim 1, wherein the medicament is manufactured for discontinuing administration of capecitabine after 24 weeks.

22. Use of neratinib and capecitabine in the manufacture of a medicament for treating a breast cancer, wherein one treatment cycle comprises 21 days and wherein the medicament is manufactured for administering neratinib orally at least one unit dose daily starting on day 1 of said cycle and capecitabine orally at least one unit dose on days 1 to 14 of said cycle.

23. A pharmaceutical composition consisting of capecitabine, neratinib, and at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential delivery for treating a neoplasm in a mammal.

24. A pharmaceutical pack for treating a neoplasm in one individual mammal, said pharmaceutical pack consisting of:

(a) at least one unit dose of capecitabine; and

(b) at least one unit dose of neratinib.

25. Use of neratinib and capecitabine in the manufacture of a medicament for treating a neoplasm, wherein the medicament is manufactured for administering neratinib in a dose range of 20 to 240 mg per day.